Research programme: apolipoprotein E-mimetic peptide therapeutics - Cognosci Inc.

Next Previous
Drug Profile

Research programme: apolipoprotein E-mimetic peptide therapeutics - Cognosci Inc.

Alternative Names: COG 112; COG 133; COG 1410; COG 241; COG 68

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke University
  • Developer Cognosci
  • Class Peptides; Small molecules
  • Mechanism of Action Apolipoprotein E agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Alzheimer's disease; Brain injuries; Multiple sclerosis; Subarachnoid haemorrhage

Highest Development Phases

  • No development reported Alzheimer's disease; Brain injuries; Chronic lymphocytic leukaemia; Multiple sclerosis; Parkinson's disease; Rheumatoid arthritis; Subarachnoid haemorrhage
  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain injuries in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top